Alexavi Glioblastoma Early Access Program

Learn About the Glioblastoma Temozolomide Gel Named Patient Early Access Program

About Glioblastoma Program


Alexavi, a biotech services company, and Double Bond Pharmaceutical are working in cooperation to make Temozolomide gel (under the brand name Temodex®) available for eligible glioblastoma patients prior to global registration. Alexavi is managing the Temozolomide gel Named Patient Early Access Program on behalf of Double Bond Pharmaceutical. Temozolomide gel is available by prescription only; physicians may contact Alexavi for more information and to place an order by filling out the form below.

Temozolomide gel is a locally acting form of the chemotherapy drug temozolomide and has been successfully tested in clinical trials. It is administered directly at the site of the tumour following surgical removal, in the form of a hydrogel, thus ensuring that the therapeutic effect occurs precisely where it is needed. Temozolomide is a prodrug which destroys the tumour’s DNA and triggers the death of tumour cells. Temodex® is currently registered in the Eurasian Economic Union, used as a first line treatment of glioblastoma in Belarus since 2014 and is intended to be used in combination with the current Standard of Care (surgery + chemoradiation) for the treatment of glioblastoma.

Glioblastoma, the most common and aggressive malignant form of all primary brain tumours, affects glial cells and accounts for 52% of all brain tissue tumour cases and 20% of all tumours inside the skull. About 50% of the patients diagnosed with glioblastoma die within one year, and 90% within three years. Temozolomide gel has shown a prolonged overall survival of 9 months in patients with glioblastoma and other malignant astrocytic, oligodendroglial and oligoastrocytic brain tumours.

Temodex® (Temozolomide gel) obtained Orphan Drug Designation from the European Medicines Agency in 2016.


Receive More Info


If you would like to receive more safety and clinical data information about Temozolomide gel, please fill out the form below and check the box for each item you would like to receive electronically. A program administrator will send you the information within 24 business hours.

Summary of Product Characteristics for Temodex® (Temozolomide gel)
Clinical study: I. Karlsson, D. Veevnik, et al. Local delivery of temozolomide via a biologically inert carrier (Temodex) prolongs survival in glioma patients, irrespectively of the methylation status of MGMT. Neoplasma 2019; 66(2): 288–293
REPORT on the conduction of a prospective, open, parallel (historical control) clinical trial of the medicinal product Temodex, powder for gel preparation for local intraoperative chemotherapy manufactured by RUE Belmedpreparaty in patients with malignant brain tumours, Phase I-II


*Required field.


Any personal data provided by you in relation to ongoing programs and the processing thereof, shall always be in line with the General Data Protection Regulation (GDPR), and in accordance with the country-specific data protection regulations as applicable.

Contact and Order


If you are interested in speaking with a program administrator about Temozolomide gel and placing an order, please fill out the form below; someone will contact you within 24 hours. Only physicians may prescribe and order Temozolomide gel.


*Required field.


Any personal data provided by you in relation to ongoing programs and the processing thereof, shall always be in line with the General Data Protection Regulation (GDPR), and in accordance with the country-specific data protection regulations as applicable.

FAQs About Temozolomide Gel Named Patient Early Access Program


QuestionResponse
What is Temozolomide gel used for?Temozolomide gel is intended to be used in combination with the current Standard of Care (surgery + chemoradiation) for the treatment of glioblastoma.
How is Temozolomide gel used?Temozolomide gel is administered directly at the site of the tumour following surgical removal, in the form of a hydrogel, thus ensuring that the therapeutic effect occurs precisely where it is needed.
What class of drug is Temozolomide gel?Temozolomide gel is a locally acting form of the chemotherapy drug temozolomide. Temozolomide is in a class of medications called alkylating agents. They work by slowing or stopping the growth of cancer cells in the body.
What is the active ingredient in Temozolomide gel? The active pharmaceutical ingredient in Temozolomide gel is an imidazotetrazine derivative of the alkylating agent dacarbazine. It is a prodrug which destroys the tumour’s DNA and triggers the death of tumour cells.
How do I order Temozolomide gel?The Early Access program should only be initiated and requested by the treating physician on behalf of a specific patient. The treatment is limited to the requested patient only and the physician who initiated the treatment request bears the liability for the treatment.

To order, contact the Temozolomide Gel Early Access Program Administrator by completing this form or emailing Temodex@AlexaviHealthcare.com

Information required will include:
• Shipping address and whose attention
• Prescription(s) or drug fulfilment request
• Payment or Purchase Order (PO) process for your facility and who the contact is for payment
• Scheduled date of patient surgery if it has been scheduled

The Temozolomide Gel Program Administrator will walk you through any additional details, questions and requirements.
What is the price of Temozolomide gel?For a price quote, please contact our Program team at Temodex@AlexaviHealthcare.com
Is there an additional price for the transport of Temozolomide gel?Transport fees will be added to the quoted (per dose) invoice.